Author of

• 17493

  +

  P2.02 - Poster Session with Presenters Present (ID 462)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Locally Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 17522

    +

    P2.02-029 - Concomitant ChemoRadiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Phase II Study from the Galician Lung Cancer Group (ID 4492)

    14:30 - 14:30  |  Author(s): E. Hernandez
    • Abstract
    • Slides

    Background:
    Concomitant platinum-based ChemoRadiotherapy (CT-RT) is the recommended treatment for unresectable locally advanced Non-Small Cell Lung Cancer (NSCLC). We conducted a phase II study to evaluate the efficacy and safety of concomitant CT-RT with cisplatin (C) and intravenous and oral vinorelbine (V) and thoracic radiotherapy.
    
    Methods:
    31 chemo-naive patients with histologically confirmed inoperable locally advanced NSCLC, stage IIIA (T4 or N2)/IIIB, PS 0-1 and adequate lung function (FEV1 > 1.1, V20 < 30%) were included in concomitant CT-RT with: C 80 mg/m2 day 1 and intravenous V 25 mg/m2 day 1 and oral V 25 mg/m2 day 8 for three cycles, during conformal thoracic radiotherapy (66 Gys, 180 cGy/day). The primary objective was overall survival (OS); secondary objectives were progression free survival (PFS), response rate (RR) and toxicity. Median follow-up: 18,1 months.
    
    Results:
    The patients characteristics were: mean age 59,6 years (44-75); male/female: 26/5; ECOG PS 0/1: 5/26; adeno/squamous/large cell carcinoma: 15/12/4; stage IIIA 16 patients and stage IIIB 15 patients. 28 patients were evaluable for response (3 patients in treatment) and 31 for toxicity. RR: 3 CR, 18 PR (RR 75%; 95% CI: 59-91), 5 SD (17.8%) and 2 PD (7.2%). The median PFS was 12 months (95% CI:6-18) and median OS was 28 months (95% CI:21-34). The PFS at 1/3 years were 47%/20% and the OS at 1/3 years were 77%/45%. Main toxicities (NCI-CTC 4.0) per patient in CT-RT (89 cycles of chemotherapy, 2.9 per patient; mean doses RT: 65,4 Gys) grade 1-2/3-4 (%) were: neutropenia 32/22.5; anemia 39/10; thrombocytopenia 13/0; nausea/vomiting 31/3; fatigue 29/0; esophagitis 39/6 and pneumonitis 16/0; hospitalizations was necesary in 9 patients: febrile neutropenia in 3 patients and grade 3 esophagitis in 2 patients.
    
    Conclusion:
    Concomitant CT-RT with Cisplatin and intravenous and oral Vinorelbine during thoracic radiotherapy is a feasible treatment option for inoperable locally advanced stage III NSCLC, showing good clinical efficacy and tolerability with acceptable long-term survival.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.